Covered recipient · General Payments record
WILLIAM J STARBIRD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$7,903.23
- Reported across 117 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $338.39 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $93.87 | 5 |
| Lilly USA, LLC | $73.32 | 4 |
| Amgen Inc. | $42.58 | 2 |
| ABBVIE INC. | $25.76 | 1 |
| Abbott Laboratories | $24.83 | 1 |
| GlaxoSmithKline, LLC. | $23.55 | 1 |
| Exact Sciences Corporation | $19.22 | 1 |
| ITI, Inc. | $18.67 | 1 |
| Acerta Pharma LLC | $16.59 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.83 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125158934 | CMS |
| ABBVIE INC. | $25.76 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106154375 | CMS |
| Amgen Inc. | $21.40 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116149013 | CMS |
| Amgen Inc. | $21.18 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116149021 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.59 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104313538 | CMS |
| Exact Sciences Corporation | $19.22 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114915728 | CMS |
| GlaxoSmithKline, LLC. | $23.55 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116204187 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.67 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326558 | CMS |
| Lilly USA, LLC | $17.22 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135515896 | CMS |
| Lilly USA, LLC | $17.79 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135515900 | CMS |
| Lilly USA, LLC | $16.51 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135472197 | CMS |
| Lilly USA, LLC | $21.80 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135515898 | CMS |
| Novo Nordisk Inc | $14.65 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096904263 | CMS |
| Novo Nordisk Inc | $17.32 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097046036 | CMS |
| Novo Nordisk Inc | $21.83 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097000124 | CMS |
| Novo Nordisk Inc | $16.28 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097371127 | CMS |
| Novo Nordisk Inc | $23.79 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097474226 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.